In the last trading session, 1.01 million shares of the G1 Therapeutics Inc (NASDAQ:GTHX) were traded, and its beta was 1.73. Most recently the company’s share price was $4.55, and it changed around $0.23 or 5.32% from the last close, which brings the market valuation of the company to $237.51M. GTHX currently trades at a discount to its 52-week high of $5.00, offering almost -9.89% off that amount. The share price’s 52-week low was $1.08, which indicates that the current value has risen by an impressive 76.26% since then. We note from G1 Therapeutics Inc’s average daily trading volume that its 10-day average is 1.04 million shares, with the 3-month average coming to 1.46 million.
G1 Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.83. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended GTHX as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. G1 Therapeutics Inc is expected to report earnings per share of -$0.21 for the current quarter.
G1 Therapeutics Inc (NASDAQ:GTHX) trade information
Instantly GTHX has showed a green trend with a performance of 5.32% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently up 49.18% year-to-date, but still up 13.75% over the last five days. On the other hand, G1 Therapeutics Inc (NASDAQ:GTHX) is 37.05% up in the 30-day period. We can see from the shorts that 2.69 million shares have been sold at a short interest cover period of 2.21 day(s).
G1 Therapeutics Inc (GTHX) estimates and forecasts
G1 Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 237.04 percent over the past six months and at a 31.18% annual growth rate that is well above the industry average of 13.00%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 60.40% in revenue this quarter, and will report a decrease of -242.90% in the next quarter. The year-over-year growth rate is expected to be -15.30%, down from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of $15.26 million in revenue for the current quarter. 5 analysts expect G1 Therapeutics Inc to make $16.41 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $12.95 million and $42.39 million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 17.90%. Forecasts for the next quarter put sales growth at -61.30%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 18.38%.
GTHX Dividends
G1 Therapeutics Inc’s next quarterly earnings report is expected to be released around May 01 and May 06.
G1 Therapeutics Inc (NASDAQ:GTHX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 11.68% of G1 Therapeutics Inc shares, and 30.18% of them are in the hands of institutional investors. The stock currently has a share float of 34.17%. G1 Therapeutics Inc stock is held by 104 institutions, with Fisher Asset Management, LLC being the largest institutional investor. By Jun 29, 2023, it held 4.91% of the shares, which is about 2.54 million shares worth $6.33 million.
JP Morgan Chase & Company, with 4.09% or 2.12 million shares worth $5.27 million as of Jun 29, 2023, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and JP Morgan Small Cap Growth Fund were the top two Mutual Funds as of Jun 29, 2023. The former held 1.3 million shares worth $3.23 million, making up 2.50% of all outstanding shares. On the other hand, JP Morgan Small Cap Growth Fund held roughly 1.23 million shares worth around $3.07 million, which represents about 2.38% of the total shares outstanding.
